Brain cancer

The FDA will close out April with five target action dates around indications that include pediatric seizures and a neurological cancer in children.

2024 began with several biopharma players posting positive Phase III data that could mean new market share for the companies and longer survival times and quality of life for patients.

Novocure’s stock spiked more than 15% Wednesday morning after the company announced its Tumor Treating Fields therapy met the primary endpoint in a late-stage trial.